WuXi Biologics (Cayman) Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WXIBF research report →
About the company
WuXi Biologics (Cayman) Inc. provides extensive global services, spanning the entire biopharmaceutical process from drug discovery to advanced development and manufacturing, catering to clients in China, North America, Europe, and other international markets. The company also offers expert consultation in biopharmaceutical technology, facilitates international sales contracting, develops and performs advanced testing services, and manages sales and marketing initiatives.
- CEO
- Zhisheng Chen
- IPO
- 2018
- Employees
- 12,575
- HQ
- Wuxi, CN
Price Chart
- Market Cap
- $19.39B
- P/E
- 27.88
- P/S
- 6.17
- P/B
- 2.90
- EV/EBITDA
- 16.19
- Div Yield
- 0.00%
- Gross Margin
- 45.98%
- Op Margin
- 30.47%
- Net Margin
- 22.53%
- ROE
- 10.64%
- ROIC
- 9.26%
- Revenue
- $21.23B · 13.67%
- Net Income
- $4.78B · 42.48%
- EPS
- $1.19 · 45.12%
- Op Income
- $6.47B
- FCF YoY
- 117.37%
- 52W High
- $5.61
- 52W Low
- $3.18
- 50D MA
- $4.27
- 200D MA
- $4.50
- Beta
- 0.58
- Avg Volume
- 401
Get TickerSpark's AI analysis on WXIBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our WXIBF coverage
Recent articles, reports, and earnings notes.
No research on WXIBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WXIBF report →Similar companies
Peers in the same neighborhood.